LNTH on Nasdaq
Lantheus Holdings, Inc.
In its 2026 annual report the company says: “We are the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Our Radiopharmaceutical Oncology product helps healthcare professionals Find, Fight and Follow cancer. Our commercial products are used by cardiologists, internal medicine physicians, neurologists, nuclear medicine physicians, oncologists, radiologists, sonographers, technologists, and urologists working in a variety of clinical settings.”5 It is headquartered in Billerica, United States.2 Its shares trade on Nasdaq under the symbol LNTH.2
Price unavailable
Last updated Oct 21, 2026.
Overview
Compare with Quidel, NeoGen or Myriad Genetics, or pick any stock.
- TickerLNTH on Nasdaq2
- IndustryIn Vitro & In Vivo Diagnostic Substances2
- HeadquartersBillerica, United States2
- Incorporated inDE3
- Business address201 Burlington Road, South Building, Bedford, Ma 017303
- Filer categoryLarge accelerated filer3
- Legal formCorporation2
- LEI5299005HUB5IOJGO7S392
- StatusActive2
- LEI statusLapsed (not renewed)2
- Registered addressc/o CORPORATION SERVICE COMPANY, 251 LITTLE FALLS DRIVE, 19808 Wilmington, United States2
- Registered withDivision of Corporations, Department of State, 44653972
See how the biggest companies compare on our leaderboards
We are the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes. We classify our products into three product categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Our Radiopharmaceutical Oncology product helps healthcare professionals (“HCPs”) Find, Fight and Follow cancer. Our Precision Diagnostic products assist HCPs to Find and Follow diseases. Our Strategic Partnerships include biomarkers and digital solutions in support of our partners’ therapeutic development, out-licensing agreements for non-core assets and optimization of our assets geographically, and contract development and manufacturing organization (“CDMO”) revenue generated by Evergreen.5 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
61.1%Gross margin6
20.2%Operating margin6
15.2%Net margin6
0.5%Revenue growth, 20256
21.4%Return on equity6
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Pylarify brought in 39% of the revenue Lantheus Holdings, Inc. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Pylarify | $851.3M | $1.1B | $989.1M |
| Radiopharmaceutical Oncology | $854.4M | $1.1B | $989.1M |
| Definity | $279.8M | $317.8M | $330.2M |
| Techne Lite | $87.4M | $95.5M | $86.8M |
| Strategic Partnerships And Other | $51.9M | $38.2M | $59.4M |
| Neuraceq [member] | $0 | $0 | $51.4M |
| License and Royalty Revenues | $33.4M | $9.1M | $34.0M |
| Other Precision Diagnostics | $23.0M | $24.2M | $24.6M |
Regions
United States brought in 95% of the revenue Lantheus Holdings, Inc. broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| United States | $1.3B | $1.5B | $1.5B |
| Outside the United States | $34.3M | $49.2M | $82.7M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue39¢$599.7M
- Research and development12¢$177.3M
- Other costs29¢$450.9M
- Income tax5¢$80.2M
- Profit15¢$233.6M
Out of $1.5B in revenue.6
Where each dollar of operating cash went, fiscal 2025
- Share buybacks77¢$300.0M
- Kept or used elsewhere23¢$90.1M
Out of $390.1M of cash from operations.6
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Noncash impairment | $1.5B | $1.5B | $1.3B |
| Cost of goods sold | $599.7M | $545.6M | $586.9M |
| Gross profit | $942.0M | $988.3M | $709.5M |
| Sales and marketing | $178.7M | $177.9M | $141.7M |
| General and administrative | $275.1M | $193.7M | $125.5M |
| Research and development | $177.3M | $168.1M | $77.7M |
| Total operating expenses | $631.1M | $539.7M | $344.9M |
| Gain on sale of assets | $0 | $8.4M | $0 |
| Operating income | $310.8M | $457.0M | $364.6M |
| Interest expense | $19.7M | $19.7M | $20.0M |
| Investment in equity securities - unrealized loss | $8.6M | $43.6M | $0 |
| Other income, net | -$31.3M | -$37.2M | -$66.3M |
| Income before income taxes | $313.8M | $431.0M | $410.9M |
| Income tax expense | $80.2M | $118.5M | $84.3M |
| Net income | $233.6M | $312.4M | $326.7M |
| Basic (in dollars per share) | $3.46 | $4.52 | $4.79 |
| Diluted (in dollars per share) | $3.41 | $4.36 | $4.65 |
| Basic (in shares) | 67.5M shares | 69.2M shares | 68.3M shares |
| Diluted (in shares) | 68.4M shares | 71.7M shares | 70.2M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $359.1M | $912.8M | $713.7M | |
| Accounts receivable, net | $358.6M | $321.3M | ||
| Inventory, net | $64.7M | $68.0M | ||
| Income tax receivable | $15.4M | $8.2M | ||
| Other current assets | $21.4M | $16.4M | ||
| Assets held for sale | $80.7M | $0 | ||
| Total current assets | $900.0M | $1.3B | ||
| Investment in equity securities | $42.2M | $39.5M | ||
| Property, plant and equipment, net | $163.7M | $176.8M | ||
| Intangibles, net | $722.8M | $161.8M | ||
| Goodwill | $239.5M | $61.2M | ||
| Deferred tax assets, net | $109.2M | $170.2M | ||
| Other long-term assets | $50.0M | $44.2M | ||
| Total assets | $2.2B | $2.0B | ||
| Current portion of long-term debt and other borrowings | $738.0K | $974.0K | ||
| Accounts payable | $42.9M | $34.6M | ||
| Accrued expenses and other current liabilities | $267.3M | $205.0M | ||
| Liabilities held for sale | $22.5M | $0 | ||
| Total current liabilities | $333.4M | $240.5M | ||
| Asset retirement obligations | $138.0K | $23.3M | $22.9M | |
| Long-term debt and other borrowings, net of current portion | $568.7M | $565.3M | ||
| Long-term deferred tax liabilities | $54.2M | $0 | ||
| Long-term contingent consideration liabilities | $73.3M | $0 | ||
| Other long-term liabilities | $107.9M | $63.2M | ||
| Total liabilities | $1.1B | $892.3M | ||
| Preferred stock ($0.01 par value, 25,000 shares authorized; no shares issued and outstanding) | $0 | $0 | ||
| Common stock ($0.01 par value; 250,000 shares authorized; 71,827 and 70,905 shares issued; 64,586 and 68,450 shares outstanding at December 31, 2025, and December 31, 2024, respectively) | $718.0K | $709.0K | ||
| Additional paid-in capital | $888.3M | $818.0M | ||
| Treasury stock at cost; 7,241 shares and 2,455 shares and 2,455 shares at December 31, 2025 and December 31, 2024, respectively | -$477.4M | -$175.0M | ||
| Retained earnings | $679.5M | $445.9M | ||
| Accumulated other comprehensive loss | -$1.3M | -$1.6M | ||
| Total stockholders equity | $1.1B | $1.1B | $815.9M | $447.1M |
| Total liabilities and stockholders equity | $2.2B | $2.0B | ||
| Preferred stock, par value (in dollars per share) | $0.01 | $0.01 | ||
| Preferred stock, shares authorized (in shares) | 25.0M shares | 25.0M shares | ||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in dollars per share) | $0.01 | $0.01 | ||
| Common stock, shares authorized (in shares) | 250.0M shares | 250.0M shares | ||
| Common stock, shares issued (in shares) | 71.8M shares | 70.9M shares | ||
| Common stock, shares outstanding (in shares) | 64.6M shares | 68.5M shares | ||
| Treasury stock, shares (in shares) | 7.2M shares | 2.5M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $359.1M | $912.8M | $713.7M | |
| Accounts receivable, net | $358.6M | $321.3M | ||
| Inventory, net | $64.7M | $68.0M | ||
| Income tax receivable | $15.4M | $8.2M | ||
| Other current assets | $21.4M | $16.4M | ||
| Assets held for sale | $80.7M | $0 | ||
| Total current assets | $900.0M | $1.3B | ||
| Investment in equity securities | $42.2M | $39.5M | ||
| Property, plant and equipment, net | $163.7M | $176.8M | ||
| Intangibles, net | $722.8M | $161.8M | ||
| Goodwill | $239.5M | $61.2M | ||
| Deferred tax assets, net | $109.2M | $170.2M | ||
| Other long-term assets | $50.0M | $44.2M | ||
| Total assets | $2.2B | $2.0B | ||
| Current portion of long-term debt and other borrowings | $738.0K | $974.0K | ||
| Accounts payable | $42.9M | $34.6M | ||
| Accrued expenses and other current liabilities | $267.3M | $205.0M | ||
| Liabilities held for sale | $22.5M | $0 | ||
| Total current liabilities | $333.4M | $240.5M | ||
| Asset retirement obligations | $138.0K | $23.3M | $22.9M | |
| Long-term debt and other borrowings, net of current portion | $568.7M | $565.3M | ||
| Long-term deferred tax liabilities | $54.2M | $0 | ||
| Long-term contingent consideration liabilities | $73.3M | $0 | ||
| Other long-term liabilities | $107.9M | $63.2M | ||
| Total liabilities | $1.1B | $892.3M | ||
| Preferred stock ($0.01 par value, 25,000 shares authorized; no shares issued and outstanding) | $0 | $0 | ||
| Common stock ($0.01 par value; 250,000 shares authorized; 71,827 and 70,905 shares issued; 64,586 and 68,450 shares outstanding at December 31, 2025, and December 31, 2024, respectively) | $718.0K | $709.0K | ||
| Additional paid-in capital | $888.3M | $818.0M | ||
| Treasury stock at cost; 7,241 shares and 2,455 shares and 2,455 shares at December 31, 2025 and December 31, 2024, respectively | -$477.4M | -$175.0M | ||
| Retained earnings | $679.5M | $445.9M | ||
| Accumulated other comprehensive loss | -$1.3M | -$1.6M | ||
| Total stockholders equity | $1.1B | $1.1B | $815.9M | $447.1M |
| Total liabilities and stockholders equity | $2.2B | $2.0B | ||
| Preferred stock, par value (in dollars per share) | $0.01 | $0.01 | ||
| Preferred stock, shares authorized (in shares) | 25.0M shares | 25.0M shares | ||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in dollars per share) | $0.01 | $0.01 | ||
| Common stock, shares authorized (in shares) | 250.0M shares | 250.0M shares | ||
| Common stock, shares issued (in shares) | 71.8M shares | 70.9M shares | ||
| Common stock, shares outstanding (in shares) | 64.6M shares | 68.5M shares | ||
| Treasury stock, shares (in shares) | 7.2M shares | 2.5M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net income | $233.6M | $312.4M | $326.7M |
| Depreciation, amortization and accretion | $70.1M | $64.6M | $60.0M |
| Impairment of long-lived assets | $0 | $0 | $138.1M |
| Adjustment to the fair value of asset retirement obligation | -$4.7M | $0 | $0 |
| Amortization of debt-related costs | $4.5M | $4.3M | $4.3M |
| Change in fair value of contingent assets and liabilities | $1.4M | -$2.7M | -$9.3M |
| Inventory adjustments | $2.2M | -$904.0K | $7.9M |
| Stock-based compensation | $85.6M | $76.4M | $50.5M |
| Gain on disposal of assets | $0 | -$8.4M | $0 |
| Gain on sale of RELISTOR licensed intangible asset | -$5.0M | $0 | -$51.8M |
| Unrealized loss on investment in equity securities | $8.6M | $43.6M | $0 |
| Charges incurred pursuant to acquired in-process research and development | $11.2M | $66.0M | $0 |
| Deferred taxes | $21.6M | -$30.0M | -$55.6M |
| Long-term indemnification receivable | $0 | $0 | $3.9M |
| Long-term income tax payable and other long-term liabilities | $246.0K | $5.2M | -$3.1M |
| Other, net | $5.2M | $12.2M | $4.9M |
| Accounts receivable | -$17.9M | -$37.7M | -$68.6M |
| Inventory | -$9.4M | -$2.7M | -$36.2M |
| Other current and noncurrent assets | -$5.4M | $4.4M | -$2.4M |
| Accounts payable | -$2.5M | -$8.8M | $17.2M |
| Accrued expenses and other current and long-term liabilities | -$9.1M | $46.8M | -$81.1M |
| Net cash provided by operating activities | $390.1M | $544.8M | $305.3M |
| Capital expenditures | -$36.1M | -$51.6M | -$46.6M |
| Acquisition of in-process research and development | -$5.4M | $0 | $0 |
| Proceeds from sale of assets | $0 | $17.8M | $97.8M |
| Acquisition of assets, net | $0 | -$80.9M | -$45.3M |
| Purchases of investment in equity securities | -$10.0M | -$83.2M | $0 |
| Acquisition of exclusive license option | $0 | -$28.0M | $0 |
| Net cash (used in) provided by investing activities | -$627.2M | -$226.0M | $5.9M |
| Payments of long-term debt and other borrowings | -$1.1M | -$318.0K | -$717.0K |
| Deferred financing costs | $0 | -$2.3M | $0 |
| Proceeds from stock option exercises | $7.2M | $3.3M | $3.8M |
| Contingent value rights settlement | $0 | $0 | -$3.7M |
| Proceeds from employee stock purchase plan | $3.7M | $3.5M | $1.9M |
| Payments for minimum statutory tax withholding related to net share settlement of equity awards | -$26.3M | -$22.6M | -$14.4M |
| Repurchase of common stock | -$300.0M | -$100.0M | $0 |
| Net cash used in financing activities | -$316.6M | -$118.5M | -$13.1M |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | -$49.0K | -$998.0K | -$93.0K |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -$553.7M | $199.2M | $298.0M |
| Interest | $15.1M | $15.1M | $15.4M |
| Income taxes , net of refunds of $28, $2,688 and $25, respectively | $69.0M | $153.8M | $151.6M |
| Additions of property, plant and equipment included in liabilities | $3.4M | $5.1M | $7.0M |
| In-process research and development included in liabilities | $5.8M | $0 | $0 |
| Contingent consideration liabilities related to acquisitions | $96.8M | $0 | $0 |
| Lease liability settled through transfer of lease | $0 | $762.0K | $0 |
| Modification of lease agreement | $5.8M | $0 | $0 |
| Right-of-use asset obtained in exchange for operating lease liabilities | $2.8M | $63.0K | $29.4M |
| Right-of-use asset obtained in exchange for finance lease obligation | $711.0K | $514.0K | $1.6M |
| Proceeds from income tax refunds | $28.0K | $2.7M | $25.0K |
No quarter-by-quarter statement was filed.
Corporate structure
Lantheus Holdings, Inc. sits at the top of its group. 33 entities, 7 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Lantheus Holdings, Inc.
- FARALLON CAPITAL MANAGEMENT, L.L.C. Filed SCHEDULE 13G/A on Lantheus Holdings, Inc., latest Aug 13, 2026
- VANGUARD PORTFOLIO MANAGEMENT LLC Filed SCHEDULE 13G on Lantheus Holdings, Inc., latest Jul 31, 2026
- Janus Henderson Group Ltd. Filed SCHEDULE 13G/A on Lantheus Holdings, Inc., latest May 15, 2026 (9 filings since Feb 14, 2024)
- VANGUARD CAPITAL MANAGEMENT LLC Filed SCHEDULE 13G on Lantheus Holdings, Inc., latest Apr 30, 2026
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on Lantheus Holdings, Inc., latest Mar 27, 2026 (5 filings since Feb 10, 2022)
- Morgan Stanley Filed SCHEDULE 13G/A on Lantheus Holdings, Inc., latest Feb 12, 2026 (2 filings since Nov 7, 2025)
- Farallon Capital Partners, L.P. Filed SCHEDULE 13G/A on Lantheus Holdings, Inc., latest Feb 5, 2026 (5 filings since Nov 14, 2024)
- FMR LLC Filed SCHEDULE 13G/A on Lantheus Holdings, Inc., latest Nov 5, 2025 (2 filings since Aug 6, 2025)
- BlackRock Filed SC 13G/A on Lantheus Holdings, Inc., latest Jan 23, 2024 (6 filings since Jan 25, 2022)
- ARMISTICE CAPITAL, LLC Filed SC 13G/A on Lantheus Holdings, Inc., latest Feb 15, 2022
- PRICE T ROWE ASSOCIATES INC /MD/ Filed SC 13G/A on Lantheus Holdings, Inc., latest Feb 14, 2022
- WELLINGTON TRUST Co N A Filed SC 13G/A on Lantheus Holdings, Inc., latest Feb 4, 2022
- Lantheus Holdings, Inc. Billerica, Massachusetts, United States
- Perspective Therapeutics, Inc. Stake · Seattle, Washington
- Radiopharm Theranostics Ltd Stake · C3
- 27 Commerce Street LLC Subsidiary · New Jersey, United States
- ACP Lantern Real Estate, LLC Subsidiary · Delaware, United States
- Aphelion LLC Subsidiary · Delaware, United States
- Cerveau Technologies, Inc. Subsidiary · Delaware, United States
- Evergreen Discovery, LLC Subsidiary · Delaware, United States
- Evergreen Theragnostics, Inc. Subsidiary · Delaware, United States
- Excelsior Life Sciences Ireland Limited Subsidiary · Ireland
- EXINI Diagnostics AB Subsidiary · Sweden
- Lantheus Alpha Therapy, LLC Subsidiary · Delaware, United States
- Lantheus EU Limited Subsidiary · Ireland
- Lantheus Five, LLC Subsidiary · Delaware, United States
- LANTHEUS MEDICAL IMAGING, INC. Subsidiary · Billerica, Massachusetts, United States
- Lantheus MI Canada, Inc. Subsidiary · Canada
- Lantheus MI Intermediate, Inc. Subsidiary · Delaware, United States
- Lantheus MI Real Estate, LLC Subsidiary · Delaware, United States
- Lantheus MI UK Limited Subsidiary · United Kingdom
- Lantheus Omega, LLC Subsidiary · Delaware, United States
- Lantheus One, LLC Subsidiary · Delaware, United States
- Lantheus Radiopharmaceuticals UK Limited Subsidiary · United Kingdom
- Lantheus Switzerland GmbH Subsidiary · Switzerland
- Lantheus Three, LLC Subsidiary · Delaware, United States
- Lantheus Two, LLC Subsidiary · Delaware, United States
- Life Molecular Imaging GmbH Subsidiary · Germany
- and 7 more
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G; stakes of 5% or more it reported on Schedules 13D and 13G (2 companies). Each entity in the chart links to its source.
What it owns
What Lantheus Holdings, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $236.5M6 Dec 31, 2025 | $285.6M6 Dec 31, 2024 | −17.2% |
| Accumulated depreciation | $72.8M6 Dec 31, 2025 | $108.8M6 Dec 31, 2024 | −33.1% |
| Property and equipment, net | $163.7M6 Dec 31, 2025 | $176.8M6 Dec 31, 2024 | −7.4% |
| Finance-lease assets | $1.3M6 Dec 31, 2025 | $1.6M6 Dec 31, 2024 | −19.4% |
| Operating-lease assets (leased space) | $31.0M6 Dec 31, 2025 | $36.1M6 Dec 31, 2024 | −14.2% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $359.1M6 Dec 31, 2025 | $912.8M6 Dec 31, 2024 | −60.7% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $239.5M6 Dec 31, 2025 | $61.2M6 Dec 31, 2024 | +291.4% |
| Intangible assets, net (excluding goodwill) | $722.8M6 Dec 31, 2025 | $161.8M6 Dec 31, 2024 | +346.8% |
| Finite-lived intangibles, gross | $687.5M6 Dec 31, 2025 | $382.3M6 Dec 31, 2024 | +79.8% |
| Accumulated amortization | $213.7M6 Dec 31, 2025 | $220.5M6 Dec 31, 2024 | −3.1% |
| Finite-lived intangibles, net | $473.8M6 Dec 31, 2025 | $161.8M6 Dec 31, 2024 | +192.9% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $64.7M6 Dec 31, 2025 | $68.0M6 Dec 31, 2024 | −4.9% |
| Raw materials | $25.9M6 Dec 31, 2025 | $29.1M6 Dec 31, 2024 | −10.8% |
| Work in process | $16.3M6 Dec 31, 2025 | $15.9M6 Dec 31, 2024 | +2.9% |
| Finished goods | $22.4M6 Dec 31, 2025 | $23.1M6 Dec 31, 2024 | −2.9% |
Properties, in its own words
The following table summarizes information regarding our significant leased and owned properties, as of December 31, 2025:
Location · Purpose · Square Footage · Ownership · Lease Term End
The rest of Item 2
United States
North Billerica, Massachusetts · Manufacturing, Laboratory, Mixed Use and Other Office Space · 354,000 · Owned (1) · N/A
Bedford, Massachusetts · Executive Offices, Laboratory, Office Space · 88,181 · Leased · February 2040
Bedford, Massachusetts · Office Space · 41,229 · Leased · July 2028
New York, New York · Office Space · 26,558 · Leased (2) · September 2030
Springfield, New Jersey · Manufacturing · 13,079 · Owned · N/A
Germany
Berlin · Office Space · 11,657 · Leased · December 2031
On January 1, 2026, we sold our single-photon emission computerized tomography (“SPECT”) business to SHINE Technologies, LLC. (“SHINE”). As a result of the sale, SHINE received 292,215 square feet of the North Billerica, Massachusetts campus that manufactures the SPECT products.
On October 11, 2021, we entered into an agreement to sublease our office space at the World Trade Center in New York City to an unrelated third party.
We believe all of these facilities are well-maintained and suitable for the office, manufacturing or warehouse operations conducted in them and provide adequate capacity for current and foreseeable future needs.
Item 2 of the 10-K filed Feb 26, 2026.5
Leadership
Who has led Lantheus Holdings, Inc., and when. Pick a name to see everywhere that person has worked.
Chief financial officer
Chief operating officer
20202025
- Chief executive officerBrian A. Markison Mar 5, 2024 to now14
- Chief executive officerJeffrey Allen Bailey Jun 24, 2015 to Sep 3, 201515
- Chief executive officerMary Anne Heino Aug 31, 2015 to Mar 5, 202416
- ChairMary Anne Heino Nov 19, 2025 to now17
- PresidentPaul Blanchfield May 22, 2023 to now18
- PresidentJeffrey Allen Bailey Jun 24, 2015 to Sep 3, 201515
- PresidentMary Anne Heino Aug 31, 2015 to Mar 10, 202316
- Chief financial officerRobert J. Marshall Jr. Oct 3, 2018 to now19
- Chief financial officerJohn W. Crowley Jan 4, 2016 to Apr 27, 201820
- Chief operating officerPaul Blanchfield Jul 19, 2022 to Mar 8, 202321
- Chief operating officerMary Anne Heino Jun 25, 2015 to Jun 25, 201522
Board members and other officers (39)
- OfficerLudger Dinkelborg Aug 18, 2025 to now23
- Chief Commercial OfficerAmanda Michelle Morgan Apr 4, 2024 to now24
- Chief Medical OfficerJeffrey Humphrey Jun 6, 2024 to Jun 20, 202425
- Chief Accounting OfficerKimberly Brown Aug 12, 2024 to now26
- Chief Medical OfficerJean-Claude Provost Jan 10, 2023 to Mar 7, 202427
- Senior Vice President, QualityCarol Walker May 10, 2021 to Apr 1, 202228
- OfficerDaniel Niedzwiecki May 10, 2021 to now29
- OfficerEtienne Montagut May 10, 2021 to Mar 7, 202430
- Chief Accounting OfficerAndrea Sabens Aug 2, 2021 to Jul 17, 202431
- Chief Human Resources OfficerYing Vivian Yao Dec 17, 2021 to Mar 7, 202232
- Chief Medical OfficerIstvan Molnar Jan 13, 2020 to Mar 8, 202133
- Chief Commercial OfficerPaul Blanchfield Jan 28, 2020 to Apr 19, 202334
- OfficerJohn J. Bolla Jun 19, 2018 to Jun 21, 202135
- OfficerMichael P. Duffy Apr 28, 2016 to May 1, 201936
- Chief Medical OfficerCesare Orlandi Jun 24, 2015 to Jul 10, 201937
- VP Finance and AccountingJohn W. Crowley Jun 24, 2015 to Sep 3, 201538
- Chief Commercial OfficerMary Anne Heino Jun 24, 2015 to Jun 24, 201539
- VP Mfrg and OperationsWilliam C. Dawes Jr. Jun 24, 2015 to Sep 1, 201740
- SVP, CommercialTimothy G. Healey Nov 17, 2015 to Mar 7, 201841
- Board memberPhuong Khanh Morrow Feb 7, 2025 to now42
- Board memberJulia Marie Eastland Sep 9, 2024 to now43
- Board memberMinnie Baylor-Henry Mar 3, 2022 to now44
- Board memberGerard Ber Jun 23, 2020 to now45
- Board memberHeinz Christoph Maeusli Jun 23, 2020 to now46
- Board memberGary J. Pruden Feb 27, 2018 to now47
- Board memberJames H. Thrall Feb 27, 2018 to now48
- Board memberKenneth Pucel Feb 27, 2018 to Mar 5, 202049
- Board memberJohn J. Bolla May 30, 2018 to May 30, 201850
- Board memberJulie McHugh Jan 26, 2017 to now51
- Board memberA. Frederick Robertson Mar 8, 2016 to Apr 30, 202152
- Board memberDerace L. Schaffer Mar 8, 2016 to Mar 5, 202053
- Board memberBrian A. Markison Jun 24, 2015 to now54
- Board memberDavid F. Burgstahler Jun 24, 2015 to Sep 11, 201755
- Board memberJeffrey Allen Bailey Jun 24, 2015 to Sep 3, 201515
- Board memberSam R. Leno Jun 24, 2015 to now56
- Board memberSriram Venkataraman Jun 24, 2015 to Mar 21, 201757
- Board memberJames C. Clemmer Jul 9, 2015 to Mar 5, 202058
- Board memberMary Anne Heino Aug 31, 2015 to now16
- General counselMichael P. Duffy Jun 24, 2015 to Apr 20, 202159
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- 27 Commerce Street LLC New Jersey4
- ACP Lantern Real Estate, LLC Delaware4
- Aphelion LLC Delaware4
- Cerveau Technologies, Inc. Delaware4
- EXINI Diagnostics AB Sweden4
- Evergreen Discovery, LLC Delaware4
- Evergreen Theragnostics, Inc. Delaware4
- Excelsior Life Sciences Ireland Limited Ireland4
- Lantheus Alpha Therapy, LLC Delaware4
- Lantheus EU Limited Ireland4
- Lantheus Five, LLC Delaware4
- Lantheus MI Canada, Inc. Canada4
- Lantheus MI Intermediate, Inc. Delaware4
- Lantheus MI Real Estate, LLC Delaware4
- Lantheus MI UK Limited United Kingdom4
- Lantheus Medical Imaging, Inc. Delaware4
- Lantheus Omega, LLC Delaware4
- Lantheus One, LLC Delaware4
- Lantheus Radiopharmaceuticals UK Limited United Kingdom4
- Lantheus Switzerland GmbH Switzerland4
- Lantheus Three, LLC Delaware4
- Lantheus Two, LLC Delaware4
- Life Molecular Imaging GmbH Germany4
- Life Molecular Imaging LLC Delaware4
All 32 listed subsidiaries
- Life Molecular Imaging Limited United Kingdom4
- MNTX Royalties Sub LLC Delaware4
- Meilleur Technologies, Inc. Delaware4
- Molecular Insight Pharmaceuticals, Inc. Delaware4
- PSMA Development Company LLC Delaware4
- Progenics Pharmaceuticals Nevada, Inc. Nevada4
- Progenics Pharmaceuticals, Inc. Delaware4
- SPECT HoldCo LLC Delaware4
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
- Lantheus MI Holdings, Inc.Mar 25, 2014 to May 23, 20143
Timeline
- Oct 2, 20268-K Other events60
- Sep 21, 20268-K Other events61
- Aug 6, 20268-K Results of operations62
- Aug 4, 20268-K Entered a material agreement; Executive or director change63
- Aug 3, 20268-K Regulation FD disclosure; Other events64
- May 7, 20268-K Results of operations65
- May 1, 20268-K Change to shareholders' rights; Executive or director change; Bylaws or fiscal year changed66
- Feb 26, 20268-K Results of operations67
- Nov 12, 20258-K Executive or director change68
- Nov 6, 20258-K Results of operations; Executive or director change; Regulation FD disclosure69
- Aug 11, 20258-K Executive or director change70
- Aug 6, 20258-K Results of operations; Regulation FD disclosure; Other events71
- Mar 5, 2024New chief executive Brian A. Markison becomes CEO14
- Aug 31, 2015New chief executive Mary Anne Heino becomes CEO16
- Jun 24, 2015New chief executive Jeffrey Allen Bailey becomes CEO15
Calendar
Coming up
- Nov 5, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported $0.99 a share, on Nov 6, 2025.72
When it reported results
- Aug 6, 2026Reported quarterly or annual results62
- May 7, 2026Reported quarterly or annual results65
- Feb 26, 2026Reported quarterly or annual results67
- Nov 6, 2025Reported quarterly or annual results69
- Aug 6, 2025Reported quarterly or annual results71
- May 7, 2025Reported quarterly or annual results73
- Feb 26, 2025Reported quarterly or annual results74
- Jan 28, 2025Reported quarterly or annual results75
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
506 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 65 major events, 270 insider forms, 36 large holders, 115 other. The latest 20:
- Oct 2, 2026DEFA14A EDGAR
- Oct 2, 20268-K EDGAR
- Sep 21, 2026DEFA14A EDGAR
- Sep 21, 20268-K EDGAR
- Sep 17, 2026DEFA14A EDGAR
- Sep 8, 2026DEFM14A EDGAR
- Sep 2, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
- Sep 2, 2026S-8 EDGAR
- Aug 26, 2026PREM14A EDGAR
- Aug 19, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
- Aug 19, 20264 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES EDGAR
- Aug 13, 2026DEFA14A EDGAR
- Aug 13, 2026SCHEDULE 13G/A EDGAR
- Aug 6, 202610-Q EDGAR
- Aug 6, 20268-K EDGAR
- Aug 4, 2026DEFA14A EDGAR
- Aug 4, 2026DEFA14A EDGAR
- Aug 4, 20268-K EDGAR
- Aug 3, 2026DEFA14A EDGAR
- Aug 3, 2026DEFA14A EDGAR
The 506 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
147 open-market trades by officers, directors and large owners since October 2021: 0 buys and 147 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 20, 2025 | WEHRLY MARK C | Sale | 3,365,000 | $56.15 | $188.9M | Form 4 |
| Aug 20, 2025 | Dapice Joshua J. | Sale | 3,365,000 | $56.15 | $188.9M | Form 4 |
| Aug 19, 2025 | WEHRLY MARK C | Sale | 41,000 | $55.34 | $2.3M | Form 4 |
| Aug 19, 2025 | Dapice Joshua J. | Sale | 41,000 | $55.34 | $2.3M | Form 4 |
| Aug 13, 2025 | Blanchfield PaulPresident | Sale | 3,060 | $53.57 | $163.9K | Form 4 |
| Jun 13, 2025 | Niedzwiecki DanielSee Remarks | Sale | 6,000 | $78.74 | $472.4K | Form 4 |
| Jun 9, 2025 | McHugh JulieDirector | Sale | 5,192 | $81.62 | $423.8K | Form 4 |
| Jun 9, 2025 | Marshall Robert J. Jr.CFO and Treasurer | Sale | 39,773 | $83.00 | $3.3M | Form 4 |
| Jun 5, 2025 | Blanchfield PaulPresident | Sale | 6,599 | $79.65 | $525.6K | Form 4 |
| Jun 5, 2025 | Niedzwiecki DanielSee Remarks | Sale | 6,000 | $79.65 | $477.9K | Form 4 |
| Jun 2, 2025 | Heino Mary AnneExecutive Chair and CEO | Sale | 26,066 | $76.83 | $2.0M | Form 4 |
| Mar 17, 2025 | Marshall Robert J. Jr.CFO and Treasurer | Sale | 10,000 | $100.52 | $1.0M | Form 4 |
| Mar 13, 2025 | Heino Mary AnneExecutive Chair and CEO | Sale | 2 | $100.13 | $200 | Form 4 |
| Mar 5, 2025 | Blanchfield PaulPresident | Sale | 2,084 | $98.00 | $204.2K | Form 4 |
| Mar 3, 2025 | Heino Mary AnneExecutive Chair and CEO | Sale | 53,107 | $94.35 | $5.0M | Form 4 |
| Jan 15, 2025 | Thrall James HDirector | Sale | 1,000 | $94.76 | $94.8K | Form 4 |
| Nov 15, 2024 | Marshall Robert J. Jr.CFO and Treasurer | Sale | 10,000 | $81.20 | $812.0K | Form 4 |
| Nov 14, 2024 | Blanchfield PaulPresident | Sale | 2,000 | $79.65 | $159.3K | Form 4 |
| Nov 8, 2024 | Heino Mary AnneExecutive Chair and CEO | Sale | 11,487 | $87.16 | $1.0M | Form 4 |
| Aug 21, 2024 | Thrall James HDirector | Sale | 1,000 | $98.52 | $98.5K | Form 4 |
All 147 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- FARALLON CAPITAL MANAGEMENT, L.L.C.SCHEDULE 13G/A, 1 filing Aug 13, 202676
- VANGUARD PORTFOLIO MANAGEMENT LLCSCHEDULE 13G, 1 filing Jul 31, 202677
- Janus Henderson Group Ltd.SCHEDULE 13G/A, 9 filings Feb 14, 2024 to May 15, 202678
- VANGUARD CAPITAL MANAGEMENT LLCSCHEDULE 13G, 1 filing Apr 30, 202679
- VANGUARD GROUP INCSCHEDULE 13G/A, 5 filings Feb 10, 2022 to Mar 27, 202680
- Morgan StanleySCHEDULE 13G/A, 2 filings Nov 7, 2025 to Feb 12, 202681
- Farallon Capital Partners, L.P.SCHEDULE 13G/A, 5 filings Nov 14, 2024 to Feb 5, 202682
- FMR LLCSCHEDULE 13G/A, 2 filings Aug 6, 2025 to Nov 5, 202583
- BlackRockSC 13G/A, 6 filings Jan 25, 2022 to Jan 23, 202484
- ARMISTICE CAPITAL, LLCSC 13G/A, 1 filing Feb 15, 202285
- PRICE T ROWE ASSOCIATES INC /MD/SC 13G/A, 1 filing Feb 14, 202286
- WELLINGTON TRUST Co N ASC 13G/A, 1 filing Feb 4, 202287
- Wellington Management CompanySC 13G/A, 1 filing Dec 10, 202188
Stakes it holds
Lantheus Holdings, Inc. has told the SEC it owns more than 5% of 2 companies, latest first (Schedules 13D and 13G).
- Perspective Therapeutics, Inc.SCHEDULE 13D/A Feb 1, 2024 to Sep 23, 202689
- Radiopharm Theranostics LtdSCHEDULE 13G Sep 4, 202690
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Dr. Ludger Dinkelborg | $227.7K | $15.3M91 | |
| 2025 | Brian A. Markison | $990.4K | $13.9M91 | |
| 2025 | Paul M. Blanchfield | $693.3K | $5.4M91 | |
| 2025 | Robert J. MarshallJr. | $697.8K | $5.2M91 | |
| 2025 | Daniel M. Niedzwiecki | $588.8K | $5.0M91 | |
| 2025 | Amanda M. Morgan | $542.0K | $3.3M91 | |
| 2025 | Mary Anne Heino | $100.0K | $2.2M91 | |
| 2024 | Former ChiefExecutive Officer | $855.0K | $13.4M91 | |
| 2024 | Chief Financial Officer and Treasurer | $669.0K | $5.4M91 | |
| 2024 | Former President | $669.0K | $5.3M91 | |
| 2024 | Chief Administrative OfficerGeneral Counsel and Corporate Secretary | $555.8K | $4.4M91 | |
| 2024 | Chief Commercial Officer | $504.8K | $2.8M91 | |
| 2024 | Executive Chairperson and Chief Executive Officer | $255.6K | $787.6K91 | |
| 2023 | Executive Chairperson and Chief Executive Officer | $873.6K | $12.6M91 | |
| 2023 | Former President | $614.5K | $5.3M91 | |
| 2023 | Chief Financial Officer and Treasurer | $569.8K | $4.3M91 | |
| 2023 | Chief Administrative OfficerGeneral Counsel and Corporate Secretary | $527.5K | $3.1M91 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| BlackRock, Inc. | 8,397,642 | $931.6M | 0.0% | +214,449 |
| Farallon Capital Management, L.l.c. | 5,583,479 | $619.4M | 3.7% | No change |
| Jupiter Topco LLC | 5,188,416 | $575.6M | 0.2% | New |
| Fmr LLC | 3,879,971 | $430.4M | 0.0% | −746,482 |
| Vanguard Portfolio Management LLC | 3,238,471 | $359.3M | 0.0% | +64,197 |
| Vanguard Capital Management LLC | 2,932,214 | $325.3M | 0.0% | +17,900 |
| American Century Companies Inc | 2,816,547 | $312.5M | 0.1% | +1,035,441 |
| State Street Corp | 2,500,696 | $277.4M | 0.0% | +70,893 |
| Geode Capital Management, LLC | 1,841,367 | $204.3M | 0.0% | +75,415 |
| Morgan Stanley | 1,726,303 | $191.5M | 0.0% | +79,840 |
| Reinhart Partners, Llc. | 1,599,379 | $177.4M | 4.1% | +34,501 |
| Dimensional Fund Advisors LP | 1,466,260 | $162.7M | 0.0% | +86,690 |
| Assenagon Asset Management S.A. | 1,429,960 | $158.6M | 0.1% | +1,297,641 |
| Citadel Advisors LLC | 1,376,480 | $152.7M | 0.1% | +1,091,936 |
| Carmignac Gestion | 1,340,100 | $148.7M | 1.9% | +12,100 |
| Swedbank AB | 1,201,243 | $133.3M | 0.1% | −27,500 |
| Wellington Management Group Llp | 1,013,063 | $112.4M | 0.0% | +244,213 |
| Brown Advisory Inc | 915,683 | $101.6M | 0.2% | +228,076 |
| UBS Group AG | 835,494 | $92.7M | 0.0% | −32,181 |
| Northern Trust Corp | 818,394 | $90.8M | 0.0% | +13,471 |
| Goldman Sachs Group Inc | 814,096 | $90.3M | 0.0% | +258,519 |
| Marshall Wace, Llp | 773,978 | $85.9M | 0.1% | +162,231 |
| Deerfield Management Company, L.P. | 752,999 | $83.5M | 1.0% | −75,000 |
| Jacobs Levy Equity Management, Inc | 699,583 | $77.6M | 0.3% | +121,938 |
| Jpmorgan Chase & Co | 699,229 | $77.0M | 0.0% | −40,244 |
13F reports cover disclosed long positions in U.S. stocks only.
Members of Congress who traded it
4 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.
| Date | Member | Trade | Amount | Vs S&P since | Filing |
|---|---|---|---|---|---|
| Jan 28, 2025 | Gilbert Ray Cisneros, Jr.Democratic, House | Buy | $1,001 - $15,000 | −17.9% | Report |
| Jan 13, 2025 | Gilbert Ray Cisneros, Jr.Democratic, House | Buy | $1,001 - $15,000 | −27.1% | Report |
| Jan 8, 2025 | Gilbert Ray Cisneros, Jr.Democratic, House | Buy | $1,001 - $15,000 | −24.6% | Report |
| Jan 7, 2025 | Gilbert Ray Cisneros, Jr.Democratic, House | Buy | $1,001 - $15,000 | −27.9% | Report |
Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).
SEC filer profile
How Lantheus Holdings, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARLantheus Holdings, Inc.1
- CIK0001521036
- Employer ID (EIN)35-23189135
- Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company5
- Incorporated inDelaware5
- Fiscal year endsDecember 311
- Industry code (SIC)2835 In Vitro & In Vivo Diagnostic Substances1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address201 Burlington Road, South Building, Bedford, MA 017301
- Phone978 671-80011
- Shares outstanding65,272,369 as of Aug 3, 202612
- Public float$4.3B as of Jun 30, 20255
- AuditorDeloitte & Touche LLP, Boston, Massachusetts PCAOB ID 34; it also attests to the company’s internal control over financial reporting5
- On EDGAR sinceMar 25, 20141
- Filings1,115 in all: 4 (540), 8-K (152), 144 (81), 3 (43), SC 13G/A (39), 10-Q (34), 425 (21), DEFA14A (20)1
All 47 form types
SC 13G (17), 4/A (15), SCHEDULE 13G/A (15), CT ORDER (12), 10-K (11), CORRESP (11), DEF 14A (11), S-8 (11), SD (11), S-1/A (9), UPLOAD (9), 424B5 (5), 424B7 (5), SCHEDULE 13G (5), ARS (4), EFFECT (4), 424B3 (2), DRS/A (2), PRE 14A (2), S-3 (2), SC 13D (2), SC 13D/A (2), SCHEDULE 13D/A (2), 10-Q/A (1), 424B4 (1), 5 (1), 8-A12B (1), 8-K/A (1), CERTNAS (1), DEFM14A (1), DRS (1), FWP (1), PREM14A (1), S-1 (1), S-1MEF (1), S-3MEF (1), S-4 (1), S-4/A (1), SCHEDULE 13D (1)
- Latest filingsAnnual report (10-K) Feb 26, 2026
Quarterly report (10-Q) Aug 6, 2026
Proxy statement (DEF 14A) Mar 20, 2026
Latest 8-K (8-K) Oct 2, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, $0.01 par value per share | LNTH | NASDAQ Global Market |
From the cover page of the 10-K filed Feb 26, 2026 (Section 12(b) of the Exchange Act).5
Risk factors and legal proceedings
The risks Lantheus Holdings, Inc. names in Item 1A of its 10-K filed Feb 26, 2026: 52 risks under these headings, as written.5
- Risks Related to Our Portfolio of Commercial Products
- We depend on some of our PMF partners to generate sales, accept, produce and deliver orders, collect payments and report related information for PYLARIFY.
- Potential generic competitors may seek to enter the market as a result of regulatory exclusivity expiration, including the expiry of NCE regulatory exclusivity for PYLARIFY in May 2026.
- If we are unable to grow the appropriate use of DEFINITY in suboptimal echocardiograms in the face of competition from other existing echocardiography agents and potential generic competitors as a result of patent and regulatory exclusivity expirations or maintain its position as the most utilized ultrasound enhancing agent.
- Our dependence upon third parties for the manufacture and supply of a substantial portion of our products, including PYLARIFY and Neuraceq, and certain key components and raw materials and upon our in-house manufacturing for DEFINITY could prevent us from delivering our products to our customers in the required quantities, within the required timeframes, or at all, which could result in order cancellations, decreased revenues and reputational harm.
- We can give no assurance that Curium Pharma (“Curium”) will continue to be successful with its commercialization of PYLCLARI in Europe or that GE Healthcare will successfully develop and commercialize piflufolastat F-18 in Japan.
- Our just-in-time manufacturing of radiopharmaceutical products, including PYLARIFY and Neuraceq, relies on the reliability of our PMFs’ equipment and processes, the timely receipt of radioactive raw materials and the timely shipment of finished goods, and any disruption of our supply or distribution networks could have a negative effect on our business.
- We face significant competition in our business and may not be able to compete effectively.
- Ultrasound enhancing agents may cause side effects which could limit our ability to sell DEFINITY.
- Risks Related to Reimbursement and Regulation
- Many of our customers are highly dependent on payments from third-party payors, including government sponsored programs, particularly Medicare, in the United States and other countries in which we operate, and reductions in third party coverage and reimbursement rates for our products (or services provided by healthcare providers using our products) could adversely affect our business, results of operations, financial condition and cash flows.
- Reforms to the United States healthcare system, including changes to policies, guidelines and practices of regulatory authorities, may adversely affect our business.
The other 42 risks
- Our business and industry are subject to complex and costly regulations. If government regulations are interpreted or enforced in a manner adverse to us or our business, we may be subject to enforcement actions, penalties, exclusion and other material limitations on our operations.
- Our marketing and sales practices may contain risks that could result in significant liability, require us to change our business practices, and restrict our operations in the future.
- Risks Related to Our Intellectual Property and Related Legal Proceedings
- We are involved in various legal proceedings that are uncertain, costly and time-consuming and could have a material adverse impact on our business, financial condition and results of operations.
- We, or our business partners, may be subject to claims that we, or our partners, have infringed, misappropriated or otherwise violated the patent or other intellectual property rights of a third party. The outcome of any of these claims is uncertain and any unfavorable result could adversely affect our business, results of operations, financial condition and cash flows.
- If we are unable to protect our intellectual property, our competitors could develop and market products with features similar to our products, and demand for our products may decline.
- Risks Related to Our Business Operations and Financial Results
- We may not be able to hire or retain the number of qualified personnel, particularly scientific, medical and sales personnel, required for our business, which would harm the expansion of our internal research and development (“R&D”) capabilities, sales of our products and approval timelines for and commercialization of our product candidates and limit our ability to grow.
- Changes to management or other key personnel, including the recent turnover in our leadership and senior management team, could have an adverse effect on our business.
- Any constraint on the availability of staff at imaging centers and hospitals and PET scanners could impact our ability to continue to generate substantial revenue from PYLARIFY, grow Neuraceq, and successfully launch and commercialize radiodiagnostic products in our pipeline.
- Our business depends on our ability to effectively manage existing products, successfully develop and launch new products and indications, generate actionable insights from data, and adapt to rapid technological and medical practice changes.
- We may be adversely affected by prevailing economic conditions and financial, business and other factors beyond our control.
- An interruption in our ability to fulfill our obligations as a service provider or supplier to third parties, either through our contract development and manufacturing operations and/or in supplying our commercial or investigational products in support of research programs being conducted by third parties, may adversely affect our reputation and business.
- Our future growth may depend on our ability to identify and acquire or in-license additional products, businesses or technologies, and if we do not successfully do so, we may have limited growth opportunities and it could result in significant impairment charges or other adverse financial consequences.
- Challenges with product quality or product performance, including defects, caused by us or our manufacturers or suppliers could result in a decrease in customers and revenues, unexpected expenses and loss of market share.
- In the ordinary course of business, we may be subject to product liability claims and lawsuits, including potential class actions, alleging that our products have resulted or could result in an unsafe condition or injury.
- We use hazardous materials in our business and must comply with environmental laws and regulations, which can be expensive.
- We face currency and other risks associated with international sales.
- Our business depends on the continued effectiveness and availability of our information technology infrastructure, and failures of this infrastructure could harm our operations.
- Our use of artificial intelligence (“AI”) or other emerging technologies could adversely affect our business, results of operations, financial condition and cash flows.
- A disruption in our computer networks, including those related to cybersecurity, could adversely affect our business, results of operations, financial condition and cash flows.
- We may be limited in our ability to utilize, or may not be able to utilize, net operating loss carryforwards to reduce our future tax liability.
- Risks Related to Our and our Strategic Partners’ Portfolios of Clinical Development Candidates
- We may not, or may take longer to, realize the expected benefits and opportunities related to, investments we have made to develop our new formulation of our prostate-specific membrane antigen (“PSMA”) PET Imaging Agent.
- We may not, or may take longer to, realize the expected benefits and opportunities related to our acquisition of the rights to LNTH-2501.
- We may not, or may take longer to, realize the expected benefits and opportunities related to, investments we have made to develop diagnostic product candidates to be used in diagnosing, staging and monitoring Alzheimer’s disease.
- We may not, or may take longer to, realize the expected benefits and opportunities related to, the POINT Biopharma Global Inc. (“POINT”) License Agreements.
- The process of developing new drugs and obtaining regulatory approval is complex, time-consuming and costly, and the outcome is not certain.
- Even if clinical development candidates receive regulatory approval, we can give no assurance that they can be successfully commercialized.
- We have been and expect to continue to be dependent on partners for the development of certain product candidates, which expose us to the risk of reliance on these partners.
- We depend on licenses from third parties for our rights to existing commercial products and to develop and commercialize certain product candidates. If we fail to achieve milestone requirements or to satisfy other conditions or otherwise have disagreements with those third parties, we may lose those rights under those license agreements, and our business, results of operations and financial condition could be adversely affected.
- Risks Related to Our Capital Structure
- Repurchases by us of our common stock may affect the value of our common stock and reduces cash available for other purposes.
- The conditional conversion feature of the 2.625% Convertible Senior Notes due December 2027, if triggered, may adversely affect our financial condition and operating results.
- The issuance or sale of shares of our common stock, or rights to acquire shares of our common stock, could depress the trading price of our common stock.
- We have indebtedness that may limit our financial and operating activities and may adversely affect our ability to incur additional debt to fund future needs.
- We may not be able to generate sufficient cash flow to meet our debt service obligations.
- Despite our indebtedness, we may incur more debt, which could exacerbate the risks described above.
- Our 2022 Revolving Facility contains restrictions that will limit our flexibility in operating our business.
- U.S. credit markets may impact our ability to obtain financing or increase the cost of future financing, including interest rate fluctuations based on macroeconomic conditions that are beyond our control.
- Our stock price has fluctuated significantly, which could cause the value of your investment in our common stock to decline, and you may not be able to resell your shares at or above your purchase price.
- Our business and operations could be negatively affected by any pending or future securities litigation or claims that we have otherwise engaged in wrongdoing.
- If securities or industry analysts do not publish research or reports about our business, if they adversely change their recommendations regarding our stock, or if our results of operations do not meet their expectations, our stock price and trading volume could decline.
- We do not anticipate paying any cash dividends for the foreseeable future, and accordingly, stockholders must rely on stock appreciation for any return on their investment.
- Anti-takeover provisions in our charter documents and Delaware law and certain provisions in the Notes and Indenture may make an acquisition of us more difficult.
Legal proceedings
Information with respect to certain legal proceedings is included in Note 17, “Commitments and Contingencies,” to the consolidated financial statements contained in Part II, Item 8. “Financial Statements and Supplementary Data,” of this Form 10-K and is incorporated herein by reference.
The opening of Item 3, Legal Proceedings.5
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17SEC EDGARMary Anne Heino, Chair
- 18SEC EDGARPaul Blanchfield, President
- 19
- 20
- 21
- 22
- 23SEC EDGARLudger Dinkelborg, Officer
- 24
- 25
- 26
- 27
- 28
- 29SEC EDGARDaniel Niedzwiecki, Officer
- 30SEC EDGAREtienne Montagut, Officer
- 31
- 32
- 33SEC EDGARIstvan Molnar, Chief Medical Officer
- 34
- 35SEC EDGARJohn J. Bolla, Officer
- 36SEC EDGARMichael P. Duffy, Officer
- 37
- 38
- 39
- 40
- 41SEC EDGARTimothy G. Healey, SVP, Commercial
- 42SEC EDGARPhuong Khanh Morrow, Board member
- 43SEC EDGARJulia Marie Eastland, Board member
- 44SEC EDGARMinnie Baylor-Henry, Board member
- 45SEC EDGARGerard Ber, Board member
- 46
- 47SEC EDGARGary J. Pruden, Board member
- 48SEC EDGARJames H. Thrall, Board member
- 49SEC EDGARKenneth Pucel, Board member
- 50SEC EDGARJohn J. Bolla, Board member
- 51SEC EDGARJulie McHugh, Board member
- 52SEC EDGARA. Frederick Robertson, Board member
- 53SEC EDGARDerace L. Schaffer, Board member
- 54SEC EDGARBrian A. Markison, Board member
- 55SEC EDGARDavid F. Burgstahler, Board member
- 56SEC EDGARSam R. Leno, Board member
- 57SEC EDGARSriram Venkataraman, Board member
- 58SEC EDGARJames C. Clemmer, Board member
- 59SEC EDGARMichael P. Duffy, General counsel
- 60SEC EDGAROther events
- 61SEC EDGAROther events
- 62SEC EDGARResults of operations
- 63
- 64
- 65SEC EDGARResults of operations
- 66
- 67SEC EDGARResults of operations
- 68SEC EDGARExecutive or director change
- 69
- 70SEC EDGARExecutive or director change
- 71
- 72NasdaqNasdaq calendar
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91